دورية أكاديمية
أعرض في EDS

How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe : Better access to medicines through HTA.

التفاصيل البيبلوغرافية
العنوان: How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe : Better access to medicines through HTA.
المؤلفون: Fontrier AM; LSE Health-Medical Technology Research Group and Department of Health Policy, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK. A.Fontrier@lse.ac.uk., Kamphuis B; LSE Health-Medical Technology Research Group and Department of Health Policy, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK., Kanavos P; LSE Health-Medical Technology Research Group and Department of Health Policy, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK.
المصدر: The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2024 Aug; Vol. 25 (6), pp. 935-950. Date of Electronic Publication: 2023 Nov 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134867 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-7601 (Electronic) Linking ISSN: 16187598 NLM ISO Abbreviation: Eur J Health Econ Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer-Verlag, c2001-
مواضيع طبية MeSH: Technology Assessment, Biomedical* , Delphi Technique* , Health Services Accessibility*, Europe ; Humans ; Pharmaceutical Preparations/supply & distribution
مستخلص: Introduction: Access to medicines is a shared goal across healthcare stakeholders. Since health technology assessment (HTA) informs funding decisions, it shapes access to medicines. Despite its wide implementation, significant access variations due to HTA are observed across Europe. This paper elicited the opinions of European stakeholders on how HTA can be improved to facilitate access.
Methods: A scoping review identified HTA features that influence access to medicines within markets and areas for improvement, while three access dimensions were identified (availability, affordability, timeliness). Using the Delphi method, we elicited the opinions of European stakeholders to validate the literature findings.
Results: Nineteen participants from 14 countries participated in the Delphi panel. Thirteen HTA features that could be improved to optimise access to medicines in Europe were identified. Of these, 11 recorded a positive impact on at least one of the three access dimensions. HTA features had mostly a positive impact on timeliness and a less clear impact on affordability. 'Early scientific advice' and 'clarity in evidentiary requirements' showed a positive impact on all access dimensions. 'Established ways to deal with uncertainty during HTA' could improve medicines' availability and timeliness, while more 'reliance on real-world evidence' could expedite time to market access.
Conclusions: Our results reiterate that increased transparency during HTA and the decision-making processes is essential; the use of and reliance on new evidence generation such as real-world evidence can optimise the availability of medicines; and better collaborations between regulatory institutions within and between countries are paramount for better access to medicines.
(© 2023. The Author(s).)
References: J Adv Nurs. 2003 Feb;41(4):376-82. (PMID: 12581103)
Open Nurs J. 2017 Oct 31;11:211-218. (PMID: 29238424)
Health Econ Rev. 2022 Jun 2;12(1):30. (PMID: 35652987)
BMC Health Serv Res. 2023 Jun 8;23(1):593. (PMID: 37291513)
Eur J Health Econ. 2018 Jan;19(1):123-152. (PMID: 28303438)
Health Qual Life Outcomes. 2019 May 22;17(1):87. (PMID: 31118091)
Front Pharmacol. 2019 Mar 29;10:196. (PMID: 30983993)
Eur J Health Econ. 2019 Apr;20(3):329-332. (PMID: 30868380)
Clinicoecon Outcomes Res. 2014 Jul 16;6:357-67. (PMID: 25075196)
MethodsX. 2020 Dec 13;8:101179. (PMID: 33365260)
Front Pharmacol. 2022 Feb 10;13:837302. (PMID: 35222045)
Arthroscopy. 2018 Feb;34(2):349-351. (PMID: 29413182)
Eur J Health Econ. 2017 Jul;18(6):715-730. (PMID: 27538758)
Int J Health Policy Manag. 2022 Aug 1;11(8):1522-1532. (PMID: 34273926)
Int J Technol Assess Health Care. 2011 Jul;27(3):261-70. (PMID: 21756414)
Clin Transl Sci. 2021 Jul;14(4):1566-1577. (PMID: 33786991)
BMC Med Res Methodol. 2007 Nov 29;7:52. (PMID: 18045508)
BMC Public Health. 2018 Apr 27;18(1):557. (PMID: 29703176)
Value Health. 2017 Mar;20(3):320-328. (PMID: 28292476)
Front Pharmacol. 2020 Dec 03;11:594549. (PMID: 33390978)
BMC Med Res Methodol. 2013 Apr 29;13:61. (PMID: 23627889)
Soc Sci Med. 2022 Aug;306:115119. (PMID: 35700552)
J Comp Eff Res. 2019 Apr;8(5):275-278. (PMID: 30892064)
BMC Med Res Methodol. 2018 Nov 19;18(1):143. (PMID: 30453902)
BMC Med Res Methodol. 2020 Jun 15;20(1):156. (PMID: 32539717)
Eur J Health Law. 2020 May 07;27(3):274-289. (PMID: 33652403)
Value Health. 2023 Oct;26(10):1474-1484. (PMID: 37385445)
Front Public Health. 2018 Dec 05;6:328. (PMID: 30568938)
J Adv Nurs. 1994 Jun;19(6):1221-5. (PMID: 7930104)
BMJ Open. 2020 Jun 28;10(6):e038145. (PMID: 32595165)
Health Policy. 2016 Oct;120(10):1115-1122. (PMID: 27628196)
Health Expect. 2021 Apr;24(2):601-616. (PMID: 33599067)
Clin Pharmacol Ther. 2019 Mar;105(3):684-691. (PMID: 30300938)
PLoS One. 2019 Dec 26;14(12):e0227132. (PMID: 31877194)
Health Policy. 2021 Mar;125(3):341-350. (PMID: 33431257)
Front Public Health. 2020 Sep 22;8:457. (PMID: 33072683)
Expert Rev Pharmacoecon Outcomes Res. 2018 Jun;18(3):297-304. (PMID: 29303374)
BMJ Open. 2014 Dec 30;4(12):e006682. (PMID: 25550297)
PLoS One. 2011;6(6):e20476. (PMID: 21694759)
J Mark Access Health Policy. 2016 Sep 27;4:. (PMID: 27857827)
MethodsX. 2021 May 28;8:101401. (PMID: 34430297)
Int J Obes (Lond). 2019 Dec;43(12):2573-2586. (PMID: 30655580)
Ecancermedicalscience. 2014 Nov 17;8:482. (PMID: 25525460)
Ann Oncol. 2016 Jan;27(1):96-105. (PMID: 26487583)
Biometrics. 1977 Jun;33(2):363-74. (PMID: 884196)
Appl Health Econ Health Policy. 2017 Jun;15(3):307-321. (PMID: 28063134)
Technol Forecast Soc Change. 2020 Aug;157:120092. (PMID: 32351256)
Value Health. 2017 Jan;20(1):67-76. (PMID: 28212972)
Value Health. 2017 Sep;20(8):1121-1130. (PMID: 28964444)
J Comp Eff Res. 2021 Nov;10(16):1187-1195. (PMID: 34583534)
Lancet. 2005 Dec 17;366(9503):2112-7. (PMID: 16360788)
Int J Technol Assess Health Care. 2018 Jan;34(3):276-289. (PMID: 29909792)
J Mark Access Health Policy. 2021 Aug 17;9(1):1964791. (PMID: 34436506)
Value Health. 2017 Apr;20(4):520-532. (PMID: 28407993)
Health Policy. 2019 Feb;123(2):118-129. (PMID: 30227974)
J Clin Epidemiol. 2014 Apr;67(4):401-9. (PMID: 24581294)
Orphanet J Rare Dis. 2020 Oct 8;15(1):277. (PMID: 33032634)
BMC Health Serv Res. 2012 Jul 09;12:193. (PMID: 22776670)
Pharmacoecon Open. 2022 May;6(3):315-328. (PMID: 34845671)
Eur J Health Econ. 2020 Jun;21(4):621-634. (PMID: 32026155)
Pharmacoecon Open. 2021 Dec;5(4):701-713. (PMID: 34216002)
فهرسة مساهمة: Keywords: Access; Delphi; Europe; HTA; Health technology assessment; Medicines
المشرفين على المادة: 0 (Pharmaceutical Preparations)
تواريخ الأحداث: Date Created: 20231102 Date Completed: 20240728 Latest Revision: 20240730
رمز التحديث: 20240730
مُعرف محوري في PubMed: PMC11283424
DOI: 10.1007/s10198-023-01637-z
PMID: 37917290
قاعدة البيانات: MEDLINE
الوصف
تدمد:1618-7601
DOI:10.1007/s10198-023-01637-z